Figure 6.

Efficacy validation of chemotherapeutics and molecularly targeted therapeutics. Changes in relative tumor volume and body weight after (A) A patient-derived xenograph (PDX) (LC-00536) was treated with doxorubicin, cisplatin, and (B) Atezolizumab for 18 days. (C) A PDX of LC-00666 was treated with afatinib for 27 days, and (D) PDX LC-00666 was treated with paclitaxel, AZD4547, and paclitaxel plus AZD4547 for 15 days when tumors reached 100˜200 mm³ post-implantation. *P < 0.05; **P < 0.01 vs. vehicle; ^##P < 0.01 vs. paclitaxel or AZD4547; ns, no significant differences vs. vehicle.